Brady Corporation to Announce Fiscal 2026 Second Quarter Financial Results on February 19, 2026

Endpoints NewsRegeneron doubles down on CytomX after other pharmas walked away

Clinical OMICsArthur Caplan: The Right to Life, Liberty, and Pursuit of Health

Endpoints NewsMineralys makes money moves before looming hypertension approval

FierceBiotechRegeneron pays $37M, adds $2B in biobucks to expand CytomX pact

PharmaVoiceWhen the ISS comes down, will its drug R&D be lost in space?

FierceBiotechAs Akeso takes center stage at ASCO, China biotech industry cements its coming of age

BioWorldSynnovation Therapeutics reports new PARG inhibitors

BioWorldFAPα inhibitors disclosed in Chomix Biotech patent

BioWorldSichuan Kelun-Biotech prepares GSPT1-degrading PROTACs

BioWorldChangchun Genescience identifies new USP30 inhibitors

BioWorldIMU’s $53M series A to advance high-definition immune profiling tech

FierceBiotechIMU Biosciences nabs $53M funding round to ‘decode’ the immune system